# Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma

> **NCT02585479** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Guangxi Medical University**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pirarubicin
- **DRUG:** Oxaliplatin
- **DRUG:** Lipiodol
- **DEVICE:** Gelfoam

## Key facts

- **NCT ID:** NCT02585479
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-10
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** It doesn't meet the requirements of randomized trials
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585479, "Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02585479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*